title: VUF-K-8788, a periphery-selective histamine H1 antagonist with anti-pruritic activities.
abstract: The pharmacological properties of 7-[3-[4-(2-quinolinylmethyl)-1-piperazinyl]-propoxy]-2,3-dihydro-4H-1,4-benzothiazin-3-one (VUF-K-8788) were investigated in vitro and in vivo. VUF-K-8788 inhibited [3H]-mepyramine from binding to the cell membrane of lung parenchyma (Ki value: 5.0 nM) and the histamine-induced contraction of isolated guinea pig ileum (pA2: 9.71) without affecting ileal contractions induced by acetylcholine, serotonin, KCl and BaCl2. The increase of vascular permeabilities induced by histamine and passive cutaneous anaphylaxis (PCA) in guinea pigs were inhibited by VUF-K-8788 in a dose-dependent fashion (ED50: 0.24 and 0.26 mg/kg, p.o., respectively). Moreover, the anti-histaminic effect of VUF-K-8788 was also observed in rats. In experiments on the effects on the central nervous system, VUF-K-8788 at 1 mg/kg, p.o. hardly antagonized the H1 receptor at all in the cerebral cortex of guinea pigs. VUF-K-8788 inhibited the PCA-induced scratching behavior completely without affecting thiopental-induced sleep in mice. These results suggested that VUF-K-8788 would be useful in the treatment of allergic disorders such as atopic dermatitis and eczema.
authors: Tokyo Research Laboratories, Pharmaceutical Division, Kowa Company, Ltd., Higashi-murayama, Japan. ttakizaw@kowa.co.jp
authors: T
authors: T
authors: Takizawa
authors: J
authors: J
authors: Matsumoto
authors: T
authors: T
authors: Tohma
authors: T
authors: T
authors: Kanke
authors: Y
authors: Y
authors: Wada
authors: M
authors: M
authors: Nagao
authors: N
authors: N
authors: Inagaki
authors: H
authors: H
authors: Nagai
authors: M Q
authors: MQ
authors: Zhang
authors: H
authors: H
authors: Timmerman
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001562:Benzimidazoles / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects; D006168:Guinea Pigs; D006632:Histamine / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D066298:In Vitro Techniques; D007665:Ketotifen / Q000494:pharmacology; D008168:Lung / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D009119:Muscle Contraction / Q000187:drug effects; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D017933:Peripheral Nervous System / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology*; D011537:Pruritus / Q000188:drug therapy*; D011738:Pyrilamine / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D016593:Terfenadine / Q000494:pharmacology; D013843:Thiazines / Q000494:pharmacology*
chemical_list: D018926:Anti-Allergic Agents; D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D010879:Piperazines; D013843:Thiazines; C121690:VUF-K 8788; D016593:Terfenadine; D006632:Histamine; C043345:emedastine; D011738:Pyrilamine; D007665:Ketotifen